🍽️ mitotane,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Cytotoxic Effects: Mitotane exerts its therapeutic effects by inhibiting the production of cortisol and other hormones by the adrenal cortex and by directly damaging adrenal cortical cells. This leads to a decrease in cortisol levels and a reduction in the size and activity of the adrenal glands, which is beneficial in the treatment of ACC.

  2. Treatment of Adrenal Cortical Carcinoma: Mitotane is considered the mainstay of therapy for patients with ACC, particularly in cases where surgical resection of the tumor is not feasible or as adjuvant therapy following surgery. It helps control tumor growth and reduce the production of adrenal hormones, which can alleviate symptoms and improve overall survival in affected individuals.

  3. Adrenal Insufficiency: Due to its suppressive effects on adrenal function, mitotane can induce adrenal insufficiency or hypocortisolism, a condition characterized by inadequate production of cortisol and other adrenal hormones. Patients receiving mitotane therapy may require replacement with glucocorticoid medications such as hydrocortisone to maintain normal physiological function.

  4. Monitoring of Hormone Levels: During mitotane therapy, patients require close monitoring of adrenal hormone levels, including cortisol, aldosterone, and adrenal androgens, to assess treatment response and adjust medication dosages as needed. Regular blood tests and clinical evaluations are necessary to prevent complications associated with hormonal imbalances.

  5. Side Effects: Common side effects of mitotane may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain, as well as neurological symptoms such as dizziness, headache, and fatigue. These side effects are often dose-dependent and may improve with dose adjustments or supportive care measures.

  6. Hepatotoxicity: Mitotane has the potential to cause liver toxicity or hepatotoxicity, manifesting as elevated liver enzyme levels (transaminases) and, rarely, more severe liver dysfunction. Liver function tests should be monitored regularly during mitotane therapy, and treatment may need to be discontinued or adjusted if significant liver abnormalities occur.

  7. Central Nervous System Effects: Mitotane can cross the blood-brain barrier and may cause central nervous system (CNS) side effects such as sedation, confusion, depression, and memory impairment. Patients should be advised to report any changes in mood or cognition to their healthcare providers for evaluation and management.

  8. Teratogenicity: Mitotane is known to be teratogenic, meaning it can cause birth defects if used during pregnancy. Female patients of childbearing potential should use effective contraception during mitotane therapy and should be counseled about the risks of fetal harm. Pregnancy should be avoided for at least several months after discontinuation of mitotane treatment.

  9. Drug Interactions: Mitotane may interact with other medications, including anticoagulants, corticosteroids, and certain antiepileptic drugs, potentially affecting their efficacy or safety. Patients should inform their healthcare providers about all medications, supplements, and herbal products they are taking to avoid potential drug interactions.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of mitotane,(prescription) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by mitotane,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Roseburia genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Lacticaseibacillus genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Clostridioides genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Phocaeicola genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Akkermansia genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Blautia genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Roseburia intestinalis species Decreases 📓 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Agathobacter rectalis species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Ruminococcus bromii species Decreases 📓 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Lacrimispora saccharolytica species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Phocaeicola vulgatus species Decreases 📓 Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Coprococcus comes species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Blautia obeum species Decreases 📓 Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Bacteroides caccae species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of mitotane,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
ADHD 2.3 0.2 10.5
Age-Related Macular Degeneration and Glaucoma 0.7 0.5 0.4
Allergic Rhinitis (Hay Fever) 0.9 0.9
Allergies 2.3 1.4 0.64
Allergy to milk products 0.9 0.5 0.8
Alopecia (Hair Loss) 1.4 1.4
Alzheimer's disease 1.8 4.8 -1.67
Amyotrophic lateral sclerosis (ALS) Motor Neuron 1.6 0.7 1.29
Ankylosing spondylitis 1.7 0.6 1.83
Anorexia Nervosa 0.5 1.9 -2.8
Antiphospholipid syndrome (APS) 1.7 1.7
Asthma 0.3 1.2 -3
Atherosclerosis 0.5 1.9 -2.8
Atrial fibrillation 2.3 0.7 2.29
Autism 6 5.3 0.13
Barrett esophagus cancer 0.3 -0.3
Bipolar Disorder 1.1 1.1 0
Brain Trauma 0.1 0.7 -6
Carcinoma 1.8 1.5 0.2
Celiac Disease 1 1.5 -0.5
Cerebral Palsy 0.8 1.2 -0.5
Chronic Fatigue Syndrome 2.3 4.2 -0.83
Chronic Kidney Disease 1.6 1.8 -0.13
Chronic Lyme 0.7 -0.7
Chronic Obstructive Pulmonary Disease (COPD) 1 0.7 0.43
Chronic Urticaria (Hives) 0.6 1 -0.67
Coagulation / Micro clot triggering bacteria 0.8 1.3 -0.63
Colorectal Cancer 2.9 0.6 3.83
Constipation 0.7 0.6 0.17
Coronary artery disease 1 0.3 2.33
COVID-19 4.6 8.4 -0.83
Crohn's Disease 3.8 4 -0.05
cystic fibrosis 0.7 -0.7
deep vein thrombosis 1.2 -1.2
Depression 5.5 6.8 -0.24
Dermatomyositis 0.3 0.3
Eczema 2 -2
Endometriosis 1.5 0.4 2.75
Epilepsy 1.6 2 -0.25
Fibromyalgia 2.3 1.4 0.64
Functional constipation / chronic idiopathic constipation 3.5 2.9 0.21
gallstone disease (gsd) 1.4 0.5 1.8
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 1.2 0.5 1.4
Generalized anxiety disorder 0.1 0.7 -6
giant cell arteritis 0.3 -0.3
Glioblastoma 0.3 -0.3
Gout 0.2 -0.2
Graves' disease 0.8 0.9 -0.13
Halitosis 0.2 0.3 -0.5
Hashimoto's thyroiditis 2.1 0.2 9.5
Hidradenitis Suppurativa 0.3 0.3
Histamine Issues,Mast Cell Issue, DAO Insufficiency 1.4 1.1 0.27
hypercholesterolemia (High Cholesterol) 0.3 0.3 0
hyperglycemia 1.2 -1.2
Hyperlipidemia (High Blood Fats) 0.3 0.1 2
hypersomnia 0.1 -0.1
hypertension (High Blood Pressure 1.7 2.1 -0.24
Hypothyroidism 0.3 -0.3
Hypoxia 0.8 0.8
IgA nephropathy (IgAN) 1.1 -1.1
Inflammatory Bowel Disease 2 7.3 -2.65
Insomnia 0.6 0.7 -0.17
Intelligence 1 1
Intracranial aneurysms 1.1 0.1 10
Irritable Bowel Syndrome 2.1 2.5 -0.19
Liver Cirrhosis 2.8 2.3 0.22
Long COVID 3.1 4.2 -0.35
Low bone mineral density 0.7 -0.7
Lung Cancer 0.1 1 -9
ME/CFS with IBS 0.6 1.1 -0.83
ME/CFS without IBS 0.7 1.8 -1.57
Metabolic Syndrome 4 4.8 -0.2
Mood Disorders 7.1 6.8 0.04
multiple chemical sensitivity [MCS] 1.1 0.1 10
Multiple Sclerosis 2.6 5.4 -1.08
Multiple system atrophy (MSA) 0.5 0.5 0
Neuropathy (all types) 0.6 0.6
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1 2.3 -1.3
Obesity 4.7 3.7 0.27
obsessive-compulsive disorder 4.4 2.4 0.83
Osteoarthritis 0.8 0.4 1
Osteoporosis 0.9 0.6 0.5
pancreatic cancer 0.3 0.3
Parkinson's Disease 1.6 3.7 -1.31
Polycystic ovary syndrome 1.9 1.8 0.06
Postural orthostatic tachycardia syndrome 0.3 0.2 0.5
Premenstrual dysphoric disorder 0.2 0.5 -1.5
primary biliary cholangitis 0.2 0.6 -2
Psoriasis 2.6 2.6 0
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 2.9 2.2 0.32
Rosacea 1.4 0.8 0.75
Schizophrenia 3.1 1.4 1.21
scoliosis 0.2 0.4 -1
Sjögren syndrome 0.9 1.9 -1.11
Sleep Apnea 0.7 1 -0.43
Small Intestinal Bacterial Overgrowth (SIBO) 0.3 0.3
Stress / posttraumatic stress disorder 1.8 1.3 0.38
Systemic Lupus Erythematosus 1.9 1 0.9
Tic Disorder 0.9 0.3 2
Tourette syndrome 0.2 0.2 0
Type 1 Diabetes 2.1 1.6 0.31
Type 2 Diabetes 4.2 5.2 -0.24
Ulcerative colitis 1.5 3.1 -1.07
Unhealthy Ageing 3.6 1.8 1

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.